EUCTR2006-005306-31-BE进行中（未招募）不适用
Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Pemetrexed and Cisplatin plus Enzastaurin versus Pemetrexed and Cisplatin plus Placebo in Chemonaive Patients with Advanced, Unresectable, or Metastatic (Stage IIIB or IV) Nonsquamous Non-Small Cell Lung Cancer - N/A
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients are eligible to be included from the study if they meet all of the following criteria:
- •[1] Have histologic or cytologic diagnosis of advanced NSCLC (Stage IIIB disease with pleural effusion and/or positive supraclavicular nodes, or Stage IV disease)
- •In addition, patients enrolling in Part 2 of the study should have the above stated diagnosis of NSCLC that is also of nonsquamous histology.
- •[2] No prior systemic chemotherapy, pleurodesis with chemotherapy, immunotherapy, targeted or biological therapy for this disease
- •[3] Have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >20 mm with conventional techniques or as >10 mm with spiral CT scan, OR nonmeasurable disease, defined according to RECIST
- •[4] Prior radiation therapy is allowed to <25% of the bone marrow; however prior radiation to the whole pelvis is not allowed. Prior radiotherapy must be completed at least 2 weeks before study enrollment. Patients must have recovered from the acute toxic effects prior to study enrollment
- •[5] Have a performance status of 0 or 1 on the Eastern Cooperative Oncology group (ECOG) scale
- •[6] Must sign an informed consent document (or legal representative has given informed consent)
- •[7] Male or female patients at least 18 years of age
- •[8] Females of child-bearing potential (not surgically sterilized and between menarche and 1 year post menopause) must test negative for pregnancy within 7 days prior to or at the time of enrollment based on a serum pregnancy test. Both males and females of reproductive potential must agree to use a reliable method of birth control, as determined by the patient and his or her health care team, during the study and for 6 months following the last dose of study treatment
- •[9] Have adequate organ function as follows:
- •Hepatic: total bilirubin =1.5 times the upper limit of normal (× ULN); alanine transaminase (ALT) alkaline phosphatase (AP) and aspartate transaminase (AST) =2.5 ×ULN (=5 × ULN, with hepatic metastases).
- •Renal: serum creatinine =1.5 × ULN; creatinine clearance =45mL/min (calculated according to Cockcroft and Gault 1976
- •Adequate bone marrow reserve: platelet count =100 × 109/L, absolute neutrophil count (ANC) =1.5 x 109/L, and hemoglobin =9.0 g/dL
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients will be excluded from the study if they meet any of the following criteria:
- •[10] Have received treatment within the last 30 days with any drug that has not received regulatory approval for any indication at the time of study entry
- •[11] Have active infection that, in the opinion of the investigator, would compromise the patient’s ability to tolerate therapy
- •[12] Have a second primary malignancy that is clinically detectable at the time of consideration for study enrollment
- •[13] Have documented central nervous system (CNS) metastases (unless the patient has completed successful local therapy for CNS metastases and has been off corticosteroids for at least 4 weeks before starting study treatment). A screening CT or MRI before enrollment in the absence of a clinical suspicion of brain metastases is not required.
- •[14] Have had myocardial infarction occurring <6 months before inclusion, uncontrolled arrhythmia, symptomatic angina pectoris, or cardiac failure not controlled by medications (refer to the New York Heart Association Class III or IV)
- •[15] Have peripheral neuropathy of NCI CTCAE Grade 2 or above
- •[16] Are unable or unwilling to discontinue use of carbamazepine, phenobarbital, or phenytoin at least 14 days prior to study therapy
- •[17] Are pregnant or breast feeding
- •[18] Are unable to swallow tablets.
- •[19] Recent (within 30 days before enrollment) or concurrent yellow fever vaccination.
- •[20] Presence of clinically significant third-space fluid collections (for example, ascites or pleural effusions) that cannot be controlled by drainage or other procedures prior to study enrollment.
- •[21] Inability to interrupt aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs), other than an aspirin dose < or =1.3 g per day, for a 5-day period (8 day period for long-acting agents, such as piroxicam).
- •[22] Inability or unwillingness to take folic acid or vitamin B12 supplementation or corticosteroids.
研究者
相似试验
进行中（未招募）
3 期
Study to evaluate the long-term safety and efficacy of the investigational drug LIB003 for the reduction of cholesterol in patients with Heterozygous Familial HypercholesterolemiaCTRI/2022/01/039679IB Therapeutics LLC
进行中（未招募）
1 期
Study to Evaluate the Long-Term Efficacy and Safety of the Investigational Drug LIB003 for the Reduction of Cholesterol in Patients With Cardiovascular Disease.Patients With Cardiovascular Disease on Stable Lipid-Lowering Therapy Requiring Additional Low-Density Lipoprotein Cholesterol ReductionMedDRA version: 20.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849EUCTR2020-004392-40-DEIB Therapeutics, LLC900
进行中（未招募）
1 期
A Clinical Trial to Evaluate the Safety and Efficacy of CCX168 (Avacopan), a new drug for the treatment of Vasculitis of a certain type, called ANCAAssociated Vasculitis (AAV).Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitisMedDRA version: 21.1Level: PTClassification code 10063344Term: Microscopic polyangiitisSystem Organ Class: 10047065 - Vascular disordersMedDRA version: 20.1Level: PTClassification code 10050894Term: Anti-neutrophil cytoplasmic antibody positive vasculitisSystem Organ Class: 10021428 - Immune system disordersMedDRA version: 21.1Level: PTClassification code 10072579Term: Granulomatosis with polyangiitisSystem Organ Class: 10047065 - Vascular disordersEUCTR2016-001121-14-ITCHEMOCENTRYX, INC.331
进行中（未招募）
不适用
Randomized, Double-Blind, Placebo-Controlled, Phase 2Study of Gemcitabine and Cisplatin Plus Enzastaurinversus Gemcitabine and Cisplatin Plus Placebo,Followed by Maintenance Enzastaurin or Placebo inChemonaive Patients with Advanced, Unresectable, orMetastatic (Stage IIIB or IV) Non-Small Cell Lung Cancer - NDEUCTR2006-005306-31-ITELI LILLY120
进行中（未招募）
1 期
Study to Evaluate the Long-Term Efficacy and Safety of the Investigational Drug LIB003 for the Reduction of Cholesterol in Patients With Cardiovascular Disease.Patients With Cardiovascular Disease on Stable Lipid-Lowering Therapy Requiring Additional Low-Density Lipoprotein Cholesterol ReductionMedDRA version: 20.1Level: LLTClassification code 10007648Term: Cardiovascular disease, unspecifiedSystem Organ Class: 100000004849EUCTR2020-004392-40-NOIB Therapeutics, LLC900